StreetInsider.com News Articles

UBS Assumes GRAIL, Inc. (GRAL) at Buy

Wed, 09 Sep 2026 06:08:38 -0400

UBS analyst Douglas Schenkel assumes coverage on GRAIL, Inc. (NASDAQ: GRAL) with a Buy rating and a price target of $105.00.

For an analyst ratings summary and ratings history on GRAIL, Inc. click here. For more ratings news on GRAIL, Inc. click here.

Shares of GRAIL, Inc. closed at $79.10 yesterday.

GRAIL, Inc. (GRAL) PT Raised to $86 at Baird

Thu, 03 Sep 2026 07:06:00 -0400

Baird analyst Catherine Schulte raised the price target on GRAIL, Inc. (NASDAQ: GRAL) to $86.00 (from $77.00) while maintaining a Outperform rating.

Form 144 GRAIL, Inc. Filed by: Ofman Joshua J.

Thu, 27 Aug 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260827/26990396.html

Form 144 GRAIL, Inc. Filed by: Ofman Joshua J.

Thu, 27 Aug 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260827/26990396.html

Form 144 GRAIL, Inc. Filed by: Freidin Aaron

Thu, 27 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260827/26990222.html

Form 144 GRAIL, Inc. Filed by: Freidin Aaron

Thu, 27 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260827/26990222.html

Form SCHEDULE 13G/A GRAIL, Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Thu, 13 Aug 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260813/26922712.html

Form SCHEDULE 13G/A GRAIL, Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Thu, 13 Aug 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260813/26922712.html

FDA panel set to review GRAIL's multi-cancer blood test application

Fri, 07 Aug 2026 11:05:17 -0400

GRAIL, Inc. (Nasdaq: GRAL) announced that the FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on Sept. 23, 2026, to review the Premarket Approval (PMA) application for its Galleri multi-cancer early detection (MCED) blood test.

GRAIL submitted the PMA application to the FDA on Jan. 29, 2026. The FDA designated Galleri as a Breakthrough Device in 2018.

The Galleri test is designed to detect cancer-specific methylation patterns across multiple cancer types before symptoms appear, including cancers without currently recommended screenings. When a cancer signal is detected, the test is designed to predict the origin

FDA panel set to review GRAIL's multi-cancer blood test application

Fri, 07 Aug 2026 11:05:17 -0400

GRAIL submitted the PMA application to the FDA on Jan. 29, 2026. The FDA designated Galleri as a Breakthrough Device in 2018.

FDA panel set to review GRAIL's multi-cancer blood test application

Fri, 07 Aug 2026 11:05:17 -0400

GRAIL submitted the PMA application to the FDA on Jan. 29, 2026. The FDA designated Galleri as a Breakthrough Device in 2018.

FDA panel set to review GRAIL's multi-cancer blood test application

Fri, 07 Aug 2026 11:05:17 -0400

GRAIL submitted the PMA application to the FDA on Jan. 29, 2026. The FDA designated Galleri as a Breakthrough Device in 2018.

GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test